Rituximab likely raises risk of hospital death in COVID-19 patients
December 2, 2021
In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”
Tocilizumab shortage continues as pandemic wears on
August 19, 2021
Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.
Patients with rheumatic disease may experience flares after SARS-CoV-2 vaccination
June 28, 2021
A total of 202 SRD flares were reported by 165 patients (14.9%).
Mavrilimumab may aid severe COVID-19 recovery
June 10, 2021
The granulocyte/macrophage-colony stimulating factor (GM-CSF) blocker reduced the need for mechanical ventilation and death by day 29 versus placebo.
Hypertension worsened by commonly used prescription meds
May 6, 2021
Close to 20% of U.S. adults with hypertension are on a prescription drug, such as NSAIDs, known to raise blood pressure, creating an opportunity for drug substitution.
More evidence MIS-C is a delayed response to SARS-CoV-2
April 13, 2021
CDC analysis of the largest cohort of MIS-C cases in the United States to date shows three temporal peaks of diagnoses in the United States and further validates the “prevailing hypothesis that MIS-C is a postinfectious mediated disorder.”
COVID-19’s impact on lupus inpatients examined in study
March 24, 2021
Younger inpatients with COVID-19 and SLE showed higher mortality than did COVID-19 inpatients of similar age from the general population in a French epidemiologic study.
RECOVERY trial of COVID-19 treatments stops colchicine arm
March 8, 2021
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.
Rheumatologic disease activity an important influencer of COVID-19 death risk
February 5, 2021
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from COVID-19.
COVID-19: Another study links colchicine to better results
February 4, 2021
Brazilian trial tested gout drug against placebo in hospitalized patients.